๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for T-cell Acute Lymphoblastic Leukemia/Lymphoma

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia NCT05281809Phase 21 site๐Ÿ“ Pittsburgh John Lister ยท Tests: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous) Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention NCT06686108Phase 21 site๐Ÿ“ Shanghai Shanghai General Hospital, Shanghai Jiao Tong University Scโ€ฆ ยท Tests: Azacitidine (AZA) Days 1 - 5, Decitabine (DAC), Venetoclax CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies NCT07106749Phase 11 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: CD180 CART Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) NCT07572136Phase 11 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: TSLPR-CART, Cyclophosphamide, Fludarabine Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL NCT06481228NA1 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: CAR-T cells, Venetoclax, Olverembatinib CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma NCT05054257Phase 11 site๐Ÿ“ Prague Institute of Hematology and Blood Transfusion, Czech Republโ€ฆ ยท Tests: Autologous CAR19 T lymphocytes VHAG in Treating R/R T-ALL/LBL NCT06742463Phase 21 site๐Ÿ“ Hangzhou First Affiliated Hospital of Zhejiang University ยท Tests: Venetoclax, homoharringtonine, Cytarabine (Ara-C), G-CSF Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL NCT06874946Phase 1, Phase 21 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: CD5-targeted CAR-T cells CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia NCT07328503Phase 21 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: CD22 CAR-transduced T cells, Cyclophosphamide, Fludarabine Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies NCT06316427Phase 1, Phase 24 sites๐Ÿ“ Beijing๐Ÿ“ Shanghai๐Ÿ“ Shanghai Beijing GoBroad Hospital ยท Tests: Autologous CD7 CAR T-cell, Prior-HSCT donor-derived CD7 CAR T-cell, New donor-derived CD7 CAR T-cell CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia NCT07361029Phase 11 site๐Ÿ“ Riyadh King Faisal Specialist Hospital & Research Center ยท Tests: CAR T cells chimeric antigen receptor cells Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia NCT03263572Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Blinatumomab, Cytarabine, Methotrexate, Ponatinib Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605Phase 21 site๐Ÿ“ Minneapolis Masonic Cancer Center, University of Minnesota ยท Tests: Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies NCT05887167Phase 11 site๐Ÿ“ Los Angeles Joshua Sasine, MD, PhD ยท Tests: autologous hematopoietic stem cells added to planned CAR T Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies NCT06904066Phase 11 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: aldesleukin, cyclophosphamide, fludarabine phosphate, Individual Patient TCR-Transduced PBL, TruSight Oncology (TSO) 500 Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations NCT07012447Phase 21 site๐Ÿ“ Suzhou yuejun Liu ยท Tests: Venetoclax, Azacitidine, Cytarabine Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies NCT07648264Phase 360 sites๐Ÿ“ Orange๐Ÿ“ Denver๐Ÿ“ Coral Springs CSL Behring ยท Tests: IgPro20 Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT NCT04746209Phase 21 site๐Ÿ“ Milwaukee Medical College of Wisconsin ยท Tests: Alpha/Beta T-cell and B-cell depleted HCT, Blinatumomab The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies NCT04329728Phase 1, Phase 211 sites๐Ÿ“ Duarte๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles AVM Biotechnology Inc ยท Tests: AVM0703 Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia NCT06446661NA1 site๐Ÿ“ Chicago University of Chicago ยท Tests: High Intensity, No Text Messagings, Low Intensity Text Messaging A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) NCT06207123Phase 1, Phase 22 sites๐Ÿ“ Chicago๐Ÿ“ Rochester University of Chicago ยท Tests: LP-118, Ponatinib, Vincristine, Dexamethasone, Methotrexate CD-19 CAR-T Cell for Pediatric ALL or Lymphoma NCT06866873NA1 site๐Ÿ“ Hong Kong Hong Kong Children's Hospital ยท Tests: CAR-T MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia NCT07371403NA1 site๐Ÿ“ Amman King Hussein Cancer Center ยท Tests: MB-CART19.1 MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies NCT05735717Phase 21 site๐Ÿ“ Minneapolis Masonic Cancer Center, University of Minnesota ยท Tests: Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma NCT07356245Phase 21 site๐Ÿ“ Columbus Jonathan Brammer ยท Tests: Ruxolitinib, Positron emission tomography-computed tomography, Bone Marrow Biopsy, Biopsy Procedure, Biospecimen Collecโ€ฆ Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies NCT06227026Phase 11 site๐Ÿ“ Salt Lake City University of Utah ยท Tests: Anti-CD19 CAR-T cells Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ฮถ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) NCT03938987Phase 1, Phase 26 sites๐Ÿ“ Calgary๐Ÿ“ Calgary๐Ÿ“ Calgary University of Alberta ยท Tests: autologous CD19-directed chimeric antigen receptor (CAR) T-cells Determining the Mechanisms of Loss of CAR T Cell Persistence NCT05809284n/a3 sites๐Ÿ“ London๐Ÿ“ London๐Ÿ“ Manchester University College, London Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies NCT07312630EARLY Phase 11 site๐Ÿ“ Hefei PersonGen BioTherapeutics (Suzhou) Co., Ltd. ยท Tests: LV009 Injection Infusion HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant NCT03326921Phase 11 site๐Ÿ“ Seattle Fred Hutchinson Cancer Center ยท Tests: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy